Aerie submits second drug for FDA approval

Aerie Pharmaceuticals has submitted its second glaucoma drug, Roclatan, to the U.S. Food and Drug Administration for potential approval. Aerie said Tuesday that it expects the FDA review period for Roclatan to be just 10 months rather than the typical 12 months because Roclatan is a fixed-dose combination of two drugs previously approved in the U.S. The move follows the commercial launch of its first drug approved by the FDA, know n as Rhopressa. The FDA approved that drug in December – two months…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news